Cell Death and Differentiation (2007) 14, 1295–1304

www.nature.com/cdd

Review

Ion channels in death and differentiation of prostate cancer cells

N Prevarskaya*,[1], R Skryma[1], G Bidaux[1], M Flourakis[1] and Y Shuba[2]

Plasma membrane ion channels contribute to virtually all basic cellular processes, including such crucial ones for maintaining tissue homeostasis as proliferation, differentiation, and apoptosis. Enhanced proliferation, aberrant differentiation, and impaired ability to die are the prime reasons for abnormal tissue growth, which can eventually turn into uncontrolled expansion and invasion, characteristic of cancer. Prostate cancer (PCa) cells express a variety of plasma membrane ion channels. By providing the influx of essential signaling ions, perturbing intracellular ion concentrations, regulating cell volume, and maintaining membrane potential, PCa cells are critically involved in proliferation, differentiation, and apoptosis. PCa cells of varying metastatic ability can be distinguished by their ion channel characteristics. Increased malignancy and invasiveness of androgen-independent PCa cells is generally associated with the shift to a 'more excitable' phenotype of their plasma membrane. This shift is manifested by the appearance of voltage-gated Na^+ and Ca^{2+} channels which contribute to their enhanced apoptotic resistance together with downregulated store-operated Ca^{2+} influx, altered expression of different K^+ channels and members of the Transient Receptor Potential (TRP) channel family, and strengthened capability for maintaining volume constancy. The present review examines channel types expressed by PCa cells and their involvement in metastatic behaviors.
Cell Death and Differentiation (2007) **14,** 1295–1304; doi:10.1038/sj.cdd.4402162; published online 4 May 2007

Historically, the first important role ascribed to plasma membrane ion channels, over 60 years ago, was their participation in cellular electrogenesis and electrical excitability. However, numerous subsequent studies have firmly established the contribution of ion channels to virtually all basic cellular behaviors, including such crucial ones for maintaining tissue homeostasis as proliferation, differentiation, and apoptosis.[1,2] The major mechanisms via which ion channels contribute to these crucial processes include: providing the influx of essential signaling ions, regulating cell volume, and maintaining membrane potential. Malignant transformation of cells resulting from enhanced proliferation, aberrant differentiation, and impaired ability to die is the prime reason for abnormal tissue growth, which can eventually turn into uncontrolled expansion and invasion, characteristic of cancer. Such transformation is often accompanied by changes in ion channel expression and, consequently, by abnormal progression of the cellular responses with which they are involved (Figure 1).

Distinctions between prostate cancer (PCa) cells of varying metastatic ability can be made according to their ion channel characteristics. Because of unrestricted accessibility and convenience of experimentation, most studies on ion channel involvement in prostate carcinogenesis have been conducted on PCa epithelial cell lines of varying metastatic potential. Many cell lines are presently established from primary tissue sources and clonal derivatives of previously established lines[3] The data from native human PCa tissues is much sparser and are usually obtained to confirm major conclusions derived from cell line studies.

In this review, we describe the major types of ion channels in PCa epithelial cells, establish their role in apoptosis- and differentiation-related events, and track down how they evolve during transformation to apoptotic-resistant cell phenotypes typical of advanced androgen-independent PCa.

Potassium Channels

Potassium channels are involved in the maintenance of resting potential, thereby they represent an integral part of all cells. As K^+ channels provide an efflux of K^+, which is the dominant cation of the intracellular medium, they are also important regulators of cell volume. K^+ channels represent one of the most diverse groups of channels, consisting of five

[1]Laboratoire de Physiologie Cellulaire, Equipe labellisée par la Ligue contre le cancer, INSERM U800, Université de Lille 1, Villeneuve d'Ascq F-59650, France and [2]Laboratory of Molecular Biophysics, Bogomoletz Institute of Physiology, NASU, Bogomoletz Street, 4, 01024 Kyiv-24, Ukraine
*Corresponding author: N Prevarskaya, Laboratoire de Physiologie Cellulaire, INSERM U800, Bâtiment SN3, USTL, 59655 Villeneuve d'Ascq, France.
Tel: +33 3 20 43 4077; Fax: +33 3 20 43 4066; E-mail: Natacha.Prevarskaya@univ-lille1.fr
Keywords: prostate cancer; ion channels; proliferation differentiation and apoptosis; volume regulation; calcium signaling; store-operated channels, TRP channels
Abbreviations: AR, androgen receptor; AVD, apoptotic volume decrease; $[Ca^{2+}]_{in}$, intracellular Ca^{2+} concentration; CRAC, Ca^{2+} release-activated channel; DAG, diacylglycerol; ER, endoplasmic reticulum; $I_{Cl,swell}$, swelling-activated Cl^- current; I_{DAG}, current through DAG-gated cationic channels; I_K, K^+ current; $I_{menthol}$, menthol-activated current through cold/menthol-sensitive TRPM8; IP_3, inositol trisphosphate; I_{SOC}, store-operated membrane current; LVA, low voltage-activated; NE, neuroendocrine; PCa, prostate cancer; PLC, phospholipase C; RVD, regulatory volume decrease; SOC, store-operated channel; SOCE, store-operated calcium entry; TEA, tetraethylammonium; TTX, tetrodotoxin; VGCC, voltage-gated Ca^{2+} channel, VGSC, voltage-gated sodium channel; VRAC, volume-regulated anion channel
Received 18.12.06; revised 02.4.07; accepted 05.4.07; Edited by P Nicotera; published online 04.5.07



Figure 1 Schematic representation of the malignant transformation of prostatic cells resulting from enhanced proliferation, NE differentiation, and apoptosis resistance. These are the prime reasons for abnormal tissue growth, which can eventually turn into uncontrolled expansion and invasion, characteristic of cancer. Such transformation is often accompanied by changes in ion channel expression and, consequently, by abnormal cellular responses

major classes: (i) voltage-gated (K_v class), (ii) Ca^{2+}-activated (K_{Ca} class), (iii) inwardly rectifying (K_{ir} class), (iv) ATP-sensitive (K_{ATP} class), and (v) background two-pore domain-containing (K_{2P} class).[4] Some of them have been identified in various types of carcinomas where they are involved in the proliferation and apoptosis of tumor cells.[4] This is consistent with the paradigm according to which the enhanced K^+ efflux is associated with apoptosis promotion and, conversely, that apoptosis is attenuated if K^+ efflux is decreased.[4–6] The mechanisms for proapoptotic effects of enhanced K^+ efflux include: (i) decay of the membrane potential and associated calcium (Ca^{2+}) overload, (ii) apoptotic cell shrinkage (apoptotic volume decrease, AVD) and activation of intracellular proapoptotic effectors.[4–6] In particular, decreases in intracellular K^+ appear to promote critical events during the early phases of cell death, including proteolytic cleavage of pro-caspase-3 and enhanced endonuclease activity.[5]

Among numerous K^+-channel types, a member of the K_v class eag1 *(ether-a-go-go*) (or K_v10.1), has been found to be involved in tumorigenesis.[7–9] eag1 K^+ channel expression is exaggerated in several human cancers, where it is invelved in cell proliferation.[9] Inhibition of endogenous eag1 commonly reduces cell proliferation, whereas heterologous overexpression enhances proliferation rate.[7]

PCa epithelial cells are generally characterized by quite prominent voltage-gated K^+ current (I_K). However, the existing data on its molecular nature are quite diverse and sometimes conflicting. This probably reflects the multichannel origin of the current as well as the multiplicity of factors that influence the patterns of their expression. Historically, in prostatic androgen-dependent LNCaP cells, the inhibition of I_K exerted antiprolifereative effects, although it did not induce apoptosis.[10–12] Comparison of prostatic androgen-dependent LNCaP and androgen-independent PC-3 cell lines has shown that increased malignancy is associated with lower density of voltage-gated K^+ current, which potentially makes their membrane 'more excitable'.[13] However, due to their combined biophysical properties and despite the fact that primary prostate carcinoma tissue has been shown to be highly enriched with eag1 mRNA and protein,[9] the endogenous I_K in PCa epithelial cells could not specifically be linked to the activity of a specific K^+-channel type.

The existing data suggests that K_v1.3 is the dominant K_v-class channel expressed in normal and cancerous rat and human prostate tissues, as well as in prostatic cell lines with different metastatic potentials, with lesser contributions from K_v1.4 and K_v1.6.[14–16] The difference between strongly metastatic rat MAT-LyLu and weakly metastatic AT-2 cell lines was again mostly found with regard to I_K density, rather than biophysical properties.[16] This is consistent with the altered expression of the same channel types as opposed to the appearance of new ones. Facilitation of K^+ efflux by K^+-channel openers, (minoxidil, 1-ethyl-2-benzimidazolinone (EBIO), or diazoxide) was able to increase growth of PC-3 cells by 30–50%, whereas K^+-channel inhibitors (dequalinium, amiodarone, and glibenclamide) caused a dose-dependent, growth inhibition of both androgen-sensitive (LNCaP, MDA-PCA-2B) and androgen-insensitive (PC-3, DU-145) human PCa cell lines.[15] The same blockers induced PC-3 apoptosis within 4 h treatment.[15]

Thus, we can conclude that PCa epithelial cells that preserve androgen sensitivity, and display relatively weak metastatic potential, are generally characterized by higher I_K and K^+-channel expression. On the one hand, this promotes their proliferation, but on the other hand it makes them more prone to programmed cell death. On the contrary, lower I_K and K^+-channel expression of highly metastatic, androgen-insensitive cells, although reducing their proliferative activity, contributes to their apoptotic resistance.

The importance of augmented K^+ efflux in apoptosis was directly confirmed in experiments with KChAP, a K^+-channel regulatory protein that increases K^+-channel expression in a 'chaperone-like' fashion in heterologous expression systems.[17] Overexpression of KChAP in LNCaP cells, decreased the average cell size due to enhanced AVD, promoted spontaneous cells apoptosis.[18] Moreover, repetitive overexpression of KChAP during 19 days in LNCaP and DU-145 tumor xenografts in nude mice significantly suppressed tumor growth due to the apoptosis of infected tumor cells. The mechanism of proapoptotic KChAP action could be due to direct interaction with K^+ channels, thereby increasing their expression. Overexpression of KChAP in LNCaP cells also produced G_0/G_1 cell-cycle arrest *via* the activation of p53 (the tumor suppressor protein) acting as a transcription factor. However, the involvement of p53 in proapoptotic KChAP activity was ruled out based on the fact that KChAP was able to induce similar apoptosis in DU-145 cells expressing mutated p53, rendering it nonfunctional as a transcription factor.[18]

Pharmacological data also suggest the presence of K_{Ca}-class channel representatives in PCa cells. Indeed, in LNCaP and PC-3 cells, the activation of K_{Ca} channels enhanced cell proliferation. The mechanism underlying the regulation of cell proliferation by IK_{Ca} channels remains to be elucidated, these results highlight the importance of Ca^{2+}-dependent K^+ efflux

in general on IK_{Ca} channels, especially in the proliferation of human PCa cells.

Interestingly, a recent electrophysiological study has also identified large-conductance (BK_{Ca}) K_{Ca} channels in LNCaP cells, although with quite unusual voltage- and $[Ca^{2+}]_{in}$-dependence. This may be due to a unique subunit composition of the channel.[19] BK_{Ca} channel expression was regulated by serum-derived factors, as serum deprivation strongly reduced whole-cell current density. Current decrease in serum-deprived medium was unaffected by either an antagonist (bicalutamide, Casodex®) or an agonist (R1881) of androgen receptor (AR), suggesting that these factors were apparently not androgens.[19] It is known that serum starvation induces neuroendocrine (NE) differentiation of LNCaP cells.[13,14] Therefore, reduction of BK_{Ca} channels may play an important role in this process, especially in light of the simultaneous increase in the expression of low-voltage-activated (LVA) calcium channels in NE cells.[13]

In conclusion, K^+ channels seem to play an important role in the control of PCa cells growth by regulating membrane potential and passive calcium influxes. However, further studies are needed to identify the precise role of each type of K^+ channels in carcinogenesis for their potential utilization as diagnostic/prognostic markers and/or therapeutic targets.

Voltage-Gated Sodium and Calcium Channels

The notion that increased malignancy of PCa cells is associated with the shift to a 'more excitable' phenotype of their plasma membrane is supported not only by the decrease in K^+ conductances, as described above, but also by the appearance of inward currents characteristic of excitable cells, such as voltage-gated Na^+ and Ca^{2+} currents. Indeed, in several PCa epithelial cells, the expression of voltage-gated Na^+ channels (VGSCs) on functional, protein and mRNA levels has been firmly established.[20–23] Moreover, VGSCs activity can enhance the metastatic behavior of cells, including their proliferation. VGSC opener veratrine has been shown to increase growth of not only androgen-insensitive PC-3 and DU-145 cells (for which functional channel activity was documented), but also of androgen-sensitive LNCaP and MDA-PCA-2B cell lines, which apparently do not display such activity.[21] At the same time, VGSC blockers (flunarizine, and riluzole) induced dose-dependent growth-inhibition of all four cell lines.[21]

RT-PCR analysis identifies tetrodotoxin-(TTX)-sensitive $Na_v1.7$ as the most upregulated (approximately 20-fold) Na^+-channel α subunit in PCa.[23] Furthermore, TTX has been shown to directly reduce the invasiveness of the cells,[17] thus suggesting Na^+ channels as a viable target for anti-PCa research. All this strongly supports the notion that expression of VGSCs and the metastatic behaviors of PCa cells are functionally related. However, the mechanism(s) responsible for VGSCs upregulation, as well as their pro-metastatic action, are still poorly understood. It is suggested that VGSCs expression may endow the membranes of PCa epithelial cells with electrophysiological properties that enhance their motility[24] and/or secretory activities,[25] as well as perturb intracellular ionic homeostasis. Indeed, it has been directly demonstrated that, whereas VGSC blockers (TTX and phenytoin) reduce, VGSC openers (aconitine, ATX II) enhance the migration of metastatic human PC-3 or rat MAT-LyLu cells without influencing the motility of weakly metastatic human LNCaP and rat AT-2 cells.[24,26] However, the questionability of pharmacological tools (i.e. specificity and side effects) may compromise the conclusions drawn; therefore, other approaches (i.e. siRNAs, overexpression studies) need to be used to conclude on the precise role of Na^+ channels in PCa.

The prostate contains an abundance of high-affinity dihydropyridine (DHP)-binding sites.[27] It has also been shown that the percentage of epithelial rat ventral prostate cells undergoing apoptosis in response to androgen ablation is reduced by administering voltage-gated Ca^{2+} channel (VGCC) blockers such as nifedipine and verapamil.[28,29] These observations have given rise to the hypothesis that calcium channel blockers, by inhibiting calcium signal-mediated apoptosis, may increase the risk of PCa.[17] Despite this indirect evidence, the presence of VGCC activity has not been detected in PCa epithelial cells by means of electrophysiology. Therefore, as in the case of Na^+ channels, the role of DHP-sensitive Ca^{2+} channels in PCa remains questionable until other experimental approaches rather than pharmacological ones, will confirm their expression and activity.

Nevertheless, the progression of Pca to the androgen-insensitivity stage is accompanied by the appearance of new apoptosis-resistant cell phenotypes. The enrichment of androgen-independent tumors with malignant NE cells should especially be noted. Fully differentiated, nonproliferating, neuron-like NE cells are a normal component of the prostate epithelium which, by releasing a variety of neurosecretory products, regulate the development and secretory activity of the prostate in the endocrine/paracrine manner.[30,31] Generally, prostatic NE cells express a variety of membrane ion channels characteristic of neurons, like TTX-resistant VGSCs, high-voltage-activated (HVA) Ca^{2+} channels of L- and N-type, K_v, K_{Ca}, and K_{ir} representatives, and are also able to generate action potentials.[32] However, an expanding population of NE cells beyond normal proportions due to the malignant transformation of epithelial/basal cells is a common characteristic of Pca progression.[30] NE cells lack nuclear AR, thereby representing an androgen-insensitive cell phenotype in the prostate.[33] They also exhibit high apoptosis resistance[34] which, according to existing evidence, is unrelated to the common antiapoptotic Bcl-2 protein,[35] and conferred instead by new survival proteins, survivin[36] and clusterin.[37]

Findings showing the small proportion of undifferentiated LNCaP cells displaying an LVA Ca^{2+} current carried by T-type Ca^{2+} channels, and the number of cells showing this type of current, as well as the significantly increased current density during the NE differentiation of LNCaP cells induced by either long-term treatments with membrane permeable cAMP analogs or by steroid-deprived culture medium[38] is of special importance. RT-PCR experiments demonstrated that only mRNA for $Ca_v3.2$ isoform of T-type Ca^{2+} channel $\alpha1$ subunit is expressed in LNCaP cells, and becomes highly elevated during NE differentiation.[38] It was also shown that basal Ca^{2+} entry through this channel at resting membrane potential due to the presence of a prominent 'window current'

is likely to facilitate neurite elongation, thereby promoting NE differentiation. It was suggested that this channel could be also involved in the stimulation of mitogenic factor secretion, thus representing an attractive potential target for future therapeutic strategies.[38] However, whether or not these channels contribute to the enhanced antiapoptotic potential of NE cells is not yet clear.

Store-operated Calcium Entry and TRP Channels

The role of Ca^{2+} in the majority of cell-signaling pathways involved in carcinogenesis is well established. Calcium homeostasis, the consequences of calcium signaling, is a steady state between influx, efflux, and storage of Ca^{2+}. From a physiological point of view, Ca^{2+} signaling is involved in the manifestation of cell phenotype, proliferation, differentiation, apoptosis, and in cellular activities such as contraction or secretion or cell excitability. Thus, each cellular phenotype, whether normal or pathological, is characterized by a particular 'Calcium Signature' reflecting its kinetics, amplitude and subcellular localization of the calcium signals. Indeed, if the oscillations of the cytosolic calcium stimulate cell proliferation via activation of the Ca^{2+}-dependent transcription factor, NFAT,[39] a sustained elevation in cytosolic Ca^{2+} concentration induces apoptosis of cancer cells[40] (Figure 2). Because the problem of Ca^{2+} homeostasis in cancer cells is too vast, even in relation to PCa cells, we will limit ourselves to characterizing channels only, and refer the reader to other comprehensive reviews for more in-depth information.[41–46]

In PCa epithelial cells, as in other nonexcitable cell types, Ca^{2+} entry from extracellular space is mainly supported by the 'capacitative calcium entry' (CCE) mechanism, also known as 'store-operated calcium entry' (SOCE) (reviewed by Parekh and Putney[47]). This mechanism is capable of monitoring edoplasmic reticulum (ER) Ca^{2+} filling, enabling influx only when ER content is essentially decreased. It is mediated via specialized plasma membrane store-operated Ca^{2+}-permeable channels (SOC). The common physiological trigger for the activation of these channels is inositol trisphosphate-(IP_3)-induced Ca^{2+} release from the ER in response to the stimulation of surface receptors coupled to the phospholipase C-(PLC)-catalyzed inositol phospholipid breakdown signaling pathway. This is why, when these channels have been identified for the first time by patch-clamp experiments, they were termed 'Ca^{2+} release-activated channels' (CRAC).[48]

Alterations in calcium homeostasis and in SOC activity seem to play a major role in the establishment of androgen-independent apoptosis-resistant phenotype of PCa. Indeed, the major features of Ca^{2+} homeostasis in androgen-independent apoptosis-resistant PCa cells (such as LNCaP cells stably transfected with Bcl-2 and NE differentiated LNCaP cells) compared to the wild-type androgen-dependent LNCaP cells are: (i) reduced basal Ca^{2+} filling of the ER pool, and (ii) reduced store-operated Ca^{2+} entry.[49] These changes were accompanied by the increased resistance to TG- and TNFα-induced apoptosis with clear shift to higher importance of Ca^{2+} influx *versus* ER store depletion in apoptosis induction compared to the wild-type androgen-dependent LNCaP cells.[49] Therefore, identification the molecular nature of SOC and the mechanisms of their activation/regulation is of great importance for understanding of what drives PCa to androgen-independence. However, years of frustration marked the quest for molecular basis of SOC and for molecules underlying the process of capacitative calcium entry. Fortunately, these questions seem to be resolved now due to the very recent series of publications on STIM1 (stomal interaction molecule 1), identified as the mammalian ER Ca^{2+}



Figure 2 Spatio-temporal regulation of Ca^{2+} signaling. This regulation is characterized by a particular 'Calcium Signature' reflecting its kinetics (duration and frequency), amplitude and subcellular localization of the calcium signals. For example, if the oscillations of the cytosolic Ca^{2+} stimulate cell proliferation via activation of the Ca^{2+}-dependent transcription factor, NFAT, a sustained elevation in cytosolic Ca^{2+} concentration induces apoptosis of cancer cells

sensor,[50,51] closely followed by identification of Orai1/CRACM1 as a component of the mammalian CRAC channel.[52] The role of these proteins in PCa progression is not yet studied, but it is obvious that STIM1 and ORAIs could represent new candidates for PCa research.

Last years, some members of the widely investigated family of mammalian homologs of the *Drosophila* TRP (transient receptor potential) channel were viewed as being involved in SOC formation (for recent reviews see Parekh and Putney,[47] Pedersen *et al.*,[53] Ramsey *et al.*[54]). Our own studies conducted on androgen-dependent LNCaP cells have suggested the involvement of the members of the 'canonical' TRP subfamily, TRPC1 and TRPC4, in prostate-specific endogenous SOCs.[55,56] However, the expression pattern of TRPC1 and TRPC4 was not modified in androgen-independent apoptosis-resistant PCa cells (Vanden Abeele *et al.*[56]). Interestingly, the activity of a member of the 'vanilloid' TRP subfamily, TRPV6, may also have some relation to the sequence of events following to ER depletion in LNCaP cells, as its antisense knockout decreases endogenous store-operated membrane current (I_{SOC}),[57,58] but the mechanisms underlying such TRPV6 activation in LNCaP cells remain elusive. However, in PCa, TRPV6, formerly known as Ca^{2+} transporter type 1 (CaT1) or epithelial calcium channel 2 (ECaC2),[59] attracts special attention even beyond its potential role in calcium influx, as its expression was shown to correlate with PCa grade.[60–62] A study conducted on tissue samples from 140 patients with PCa demonstrated the association of TRPV6 with PCa progression and suggested it as a prognostic molecular marker in cancer classification.[60] Moreover, it has been demonstrated that heterologous TRPV6 expression in HEK-293 cells promotes their proliferation in a Ca^{2+}-dependent manner by increasing $[Ca^{2+}]_{in}$ levels, which is a prerequisite for its potential role in tumor progression.[63] It seems, however, that the functional role of endogenous TRPV6 in prostatic I_{SOC} is closely linked to other potential SOC constituents and/or regulators, because heterologous TRPV6 overexpression in LNCaP cells resulted in the appearance of additional membrane current with properties distinct from endogenous I_{SOC}.[64] In any event, the problem of molecular basis for SOCE in PCa epithelial cells is still far from being resolved.

It is well established that various cellular Ca^{2+}-dependent processes rely on the specific spatial and temporal patterns of Ca^{2+} signaling.[65] However, the type and manner of their organization during carcinogenesis is not sufficiently defined. For instance, in PCa epithelial cells, stimulation of two receptors, α1-adrenoceptor (α1-AR) and metabotropic purinergic receptor (P2Y-R), produce divergent effects on cell proliferation: α1-AR stimulation enhances proliferation,[39,66] whereas P2Y-R stimulation results in growth arrest.[40,66] Such divergent effects on proliferation are quite surprising, given that both receptors act *via* a common PLC-catalyzed inositol phospholipid breakdown signaling pathway that results in the derivation of IP_3 and diacylglycerol (DAG), two second messengers important for Ca^{2+} signaling. Our recent studies on primary human PCa epithelial cells provided some understanding of these puzzling observations.[66] We have shown that Ca^{2+} signaling controlled by each receptor relies on different Ca^{2+}-entry pathways, ultimately targeting various intracellular effectors. It appeared that stimulation of α1-AR activates plasma membrane nonspecific cationic channels via direct DAG gating,[39,66] without affecting ER Ca^{2+} stores, whereas P2Y-R stimulation brings about IP_3 receptor-mediated ER store depletion and activation of SOCs.[40,66] Consistent with these peculiarities, the α1-AR agonist, phenylephrin, stimulated oscillatory-type intracellular Ca^{2+} signaling involving membrane current through DAG-gated cationic channels (I_{DAG}), whereas the P2Y-R agonist, ATP, induced a transient $[Ca^{2+}]_{in}$ increase, followed by a smaller sustained increase due to store depletion and SOC activation (Figure 3). The two Ca^{2+} entry pathways also appeared to have a different molecular nature, with the first one mostly relying on a DAG-gated TRP member, TRPC6, and the second one on TRPC1 and TRPC4.

Moreover, our data show that α1-AR stimulation enhances Pca epithelial cell proliferation by inducing store-independent, TRPC6-mediated Ca^{2+} entry resulting in the activation of NFAT transcription factor via its Ca^{2+}/calmodulin/calcineurin nuclear translocation pathway.[66] TRPC6 antisense knockout exerted effects similar to those of pharmacological α1-AR inhibition, that is, suppression of agonist-induced Ca^{2+} entry, cessation of oscillatory-type Ca^{2+} signaling, and consequent termination of cell proliferation. Furthermore, chronic treatment with α1-agonists enhanced TRPC6 protein expression, as well as altered the expression of two cell-cycle regulators, CDK4 and cyclin-dependent kinase inhibitor p27. This provides direct evidence for the α1-AR–TRPC6–NFAT–cell proliferation link. In contrast, Ca^{2+} entry associated with P2Y-R stimulation by extracellular ATP and related growth arrest did not involve either TRPC6 channel activation or NFAT translocation. Our findings demonstrate that the α1-AR-dependent Ca^{2+} signaling that promotes proliferation of Pca epithelial cells specifically requires the activation of TRPC6 channels coupled to NFAT, thereby suggesting TRPC6 as a promising new target for controlling Pca cell proliferation.

It should be noted that clinical studies also implicate α1-AR antagonists as proapoptotic agents capable of inducing apoptosis of human Pca epithelial and smooth muscle cells without affecting cellular proliferation.[67] However, these effects seem to be unrelated to α1-AR[68] and Ca^{2+} signaling associated with it.

Interestingly, the endogenous expression of TRPC1, TRPC3, and TRPV6 proteins *per se* in LNCaP cells was shown to controlled by the ER Ca^{2+} filling: after a prolonged (24–48 h) depletion of the stores with thapsigargin, a potent proapoptotic agent, their expression increased.[69] Enhanced expression of apparently store-dependent TRP members under ER store depletion is difficult to reconcile with the findings that androgen-independent, apoptosis-resistant PCa cell phenotypes, for which chronic underfilling of the ER Ca^{2+} pool represents a new level of equilibrium helping them to withstand ER stress-mediated apoptosis, are characterized by reduced SOCE.[49,70,71] It is, therefore, likely that native SOC in Pca epithelial cells is a much more complex entity, whose functional expression cannot be directly correlated with any of the implicated TRP members. In this respect, it is important to assess the role of STIM1 and CRACM1 (Orai1) proteins in PCa cell SOCE.



Figure 3 Differential role of TRP channels in agonist-stimulated calcium signaling and PCa cell proliferation. (**a**) Typical pattern of cytosolic Ca^{2+} oscillations induced in primary cultured human PCa epithelial cells by the agonist of α1-adrenergic receptors (α1-AR), phenylephrine (PHE, 10 μM); the importance of Ca^{2+} entry for supporting oscillatory activity and the inability of PHE-to induced Ca^{2+} release is evidenced by the lack of any signal in the absence of extracellular Ca^{2+} ($0Ca^{2+}$); cells incubated in the presence of PHE (10 μM) for 2 days enhanced proliferation by almost 40% compared to control conditions (CTL) (**c**). (**b**) The shape of cytosolic Ca^{2+} signal in primary cultured human PCa epithelial cells induced by the purinergic receptor (P2Y-R) agonist, ATP (10 μM); in the absence of extracellular Ca^{2+} ($0Ca^{2+}$), ATP mobilizes of intracellularly stored Ca^{2+}, followed by quasi-sustained store-operated Ca^{2+} entry upon re-exposure to Ca^{2+} ($2Ca^{2+}$); cell culturing in the presence of ATP (100 μM) for 2 days delayed proliferation by 60% (**c**). (**c**) The effects of two agonists on human PCa epithelial cell proliferation. (**d** and **e**) Antisense knockout of store-independent, DAG-gated TRP member, TRPC6, does not affect ATP-induced Ca^{2+} signals (measured as maximal $[Ca^{2+}]_i$ increase in the presence of 2 mM Ca^{2+}), but greatly attenuates PHE-induced ones (because of its oscillatory nature measured as an integral of $[Ca^{2+}]_i$ over a 30-min period) (**d**), and *vice versa*, similar knockout of a store-dependent TRP member, TRPC1, significantly reduces the ATP-evoked Ca^{2+} signal, but leaving the PHE-induced one unaffected (**e**)

Cold/menthol-sensitive TRPM8 of the 'melastatin' TRP subfamily is yet another TRP member that has recently emerged as an important player in normal and pathological development of the prostate, whose real significance, however, is only beginning to unfold. Although TRPM8 was initially identified as a cold/menthol receptor mediating cold-evoked excitation in sensory neurons,[72,73] in fact, it was first cloned from the human prostate as a prostate-specific gene[74] before its role in cold sensation was established. Our data,[75] as well as those of others,[76] indicate that TRPM8 is expressed not only in the plasma membrane of prostate cells, as initially anticipated, but also in the ER membrane, where it operates as an ER Ca^{2+} release channel involved in the activation of SOCE in response to cold/menthol stimulus. Moreover, whereas remaining at moderate levels in a normal prostate, TRPM8 expression strongly increases in Pca. For this reason, it has been proposed to be a pro-oncogenic actor in PCa cells.[74] Other nonprostatic primary human tumors (breast, colon, lung, and skin) also become highly enriched in TRPM8, although it is virtually undetectable in corresponding normal tissues.[74] Thus, even this initial information strongly pointed to much broader roles of TRPM8 beyond cold sensation, especially in the prostate and during carcinogenesis. The role of TRPM8 in organs not exposed to ambient temperatures, and especially in prostate gland, remains a gnawing mystery. However, the data accumulated last years allow hypothesizing on that.

In normal prostate, *trpm8* gene expression seems to be directly controlled by AR,[76,77] positioning it as a primary androgen-response gene.[77] Single-cell RT-PCR and immunohistochemical experiments conducted on primary human PCa cells have shown that TRPM8 is mainly expressed in androgen-dependent, apical secretory epithelial cells, and that its expression becomes downregulated in cells loosing the AR activity and regressing to the basal epithelial phenotype.[77] Mature epithelial cells are nonproliferative cells, highly sensitive to apoptotic stimuli (due to the specific regulation of the expression of genes belonging to *Bcl-2* family: antiapoptotic *Bcl-2* gene expression is repressed, whereas proapoptotic *Bax* gene expression is stimulated by AR).[78–80] Nevertheless, the secretion of products (including citric acid, prostate-specific antigen (PSA), acid phosphatase, several enzymes and lipids) is the major function of apical epithelial prostate cells. Therefore, considering the specific TRPM8 expression in these cells, we suggested the potential role of this channel in secretion.

In PCa tumors, a significant difference in mRNA expression level of TRPM8 between malignant and nonmalignant tissue specimens has been detected.[81] This was comparable to the currently used PCa marker, PSA, thus, qualifying TRPM8 as its potential competitor in PCa diagnosis and staging. A significant difference in TRPM8 expression between human benign prostate hyperplasia and PCa tissues is also obvious at protein level (Figure 4). According to Tsavaler's hypothesis defining *trpm8* as an oncogene,[74] TRPM8 overexpression and overactivity in circumscribed, androgen-dependent PCa may be correlated to the higher rate of growth of these cells compared to normal ones.[82,83] During the transition to



Figure 4 PCa-specific enhancement of cold/menthol-sensitive TRPM8 channel expression. (**a** and **b**) Confocal images of human benign prostate hyperplasia (BPH, **a**) and PCa (**b**) tissue samples stained with TRPM8-specific antibody (code: ab3243, Abcam, Cambridge, UK) showing much higher TRPM8 protein expression in PCa

androgen independence, TRPM8 is lost in xenograft model and also in PCA tissue from patients treated preoperatively with antiandrogen therapy, suggesting that its loss may be associated with a more advanced form of the disease.[84] According to a clinical study describing that androgen-independent PCa metastasis proliferate more slowly than the androgen-dependent ones,[83] our unpublished results demonstrated that LNCaP cells resistant to anti-androgen bicalutamide treatment (LNCaP-bic^R) displayed a reduced doubling time. This is correlated to a decreased expression of AR, TRPM8 and the proliferating cell nuclear antigen (PCNA) mRNAs, whereas antiapoptotic Bcl-2 mRNA expression is increased (Figure 5). All these data reinforce the putative proproliferative role of TRPM8 in androgen-dependent PCa cells.

Finally, Barritt's group has demonstrated that both pharmacological activation of TRPM8 and siRNA-mediated TRPM8 silencing in LNCaP cells can decrease the cell viability,[76] probably by perturbing the TRPM8-dependent intracellular Ca^{2+} homeostasis. However, it is still not clear whether TRPM8 involvement in cell viability is carried out through a proproliferative and/or an antiapoptotic mechanism.



Figure 5 Transition of metastatic PCa cells to androgen-independence leads to a decreased proliferation and strong shifts in gene expression. (**a**) Comparison of doubling time of LNCaP cell line and of an LNCaP subclone resistant to bicalutamide treatment (LNCaP-bic^R obtained after a 10-month 100 μM bicalutamide selection). Addition of 20 μM bicalutamide increased the doubling time of LNCaP cells, but do not affect the proliferation of LNCaP-bic^R. (**b**) Normalized expression of AR, TRPM8, Bcl-2, and PCNA mRNA in both LNCaP cells and LNCaP-bic^R cells figured out with PCR experiment. LNCaP-bic^R cells displayed a significant decrease of AR, TRPM8 and cell-cycle-associated PCNA expression, although antiapoptotic Bcl-2 mRNA level was increased

Chloride Channels

Activation of the chloride current through specialized volume-regulated anion channels (VRACs) in response to cell swelling ($I_{Cl,swell}$) is one of the major mechanisms by which cells tend to restore their volume following hypo-osmotic stress – a process known as regulatory volume decrease (RVD) (reviewed by Furst *et al.*,[85] Okada *et al.*[86]). Extracellular osmotic perturbations are not the only reason for alterations in cell volume. Effectively counteracting abrupt volume changes and maintaining relative volume constancy during active solute uptake, exocytosis, proliferation, and differentiation are major prerequisites for cell survival. Indeed, there is strong evidence that disordered or altered cell volume regulation is associated with apoptosis.[86] Compelling support for such an association has been provided by demonstrating the direct causal link between apoptotic resistance conferred by antiapoptotic Bcl-2 protein and the strengthening of RVD capability due to upregulation of $I_{Cl,swell}$.[87,88]

Using LNCaP cells, we have shown that PCa cells are endowed with the powerful $I_{Cl,swell}$, which provides an effective RVD under hypoosmotic stress,[89,90] and that the magnitude of this current, as well as the capability of an even further increase in RVD with cell transition to androgen-independence and apoptosis resistance.[88,91] Moreover, the enhancement of $I_{Cl,swell}$ and the related strengthening of RVD appeared to be independent on the specific reasons for such a transition: overexpression of the common antiapoptotic Bcl-2 protein or NE differentiation, suggesting that it represents a general phenomenon.

Although the molecular nature of native $I_{Cl,swell}$-carrying VRACs is not known, and several membrane proteins are considered as potential candidates,[85,86] our data are also consistent with ClC-3 protein[92] involvement in



Figure 6 Summary of membrane currents and respective ion channels in prostate cancer (PCa) epithelial cells and their involvement in metastatic behaviors of androgen-sensitive and androgen-insensitive cell phenotypes.'↑' denotes upregulation, '↓' – downregulation, '?' – information is not available; channel designations correspond to accepted nomenclatures; all other abbreviations are presented in the abbreviations list

prostate-specific VRAC, as well as with its upregulation in androgen-independent PCa cell phenotypes.[88,91] Importantly, it appears that Ca^{2+} homeostasis and volume homeostasis of PCa cells are interrelated due to functional coupling of SOCs and VRACs in confined plasma membrane caveolae microdomains,[56] enabling Ca^{2+} entering the cell *via* SOCs to exert inhibitory action on VRACs.[90] Such coupling is partly responsible for the upregulation of $I_{Cl,swell}$ in androgen-insensitive, apoptosis-resistant PCa cell phenotypes. Indeed, these cells are generally characterized by reduced I_{SOC}, most likely due to the diminished number of functional SOCs.[49,70,71] Therefore, less baseline inhibition of VRACs is expected. In turn, downregulation of SOCs and SOCE in androgen-insensitive, apoptosis-resistant PCa cells apparently represents an adaptive response to chronic underfilling of their ER Ca^{2+} pools resulting from enhanced ER leak, accompanied by the decreased expression of ER luminal Ca^{2+}-binding protein, calreticulin, and SERCA2b Ca^{2+} pump isoform.[49,70]

Conclusions

Figure 6 presents a summary of various membrane currents and associated ion channels identified in PCa cells, and their possible involvement in metastatic behavior. All of these channels potentially represent attractive targets for diagnosis, staging and/or treatment of PCa. However, more studies are needed, especially in *in vivo* systems, before any of them will result in practical implications.

Acknowledgements. This work was supported by grants from INSERM, the French Minsistry of Education, La Ligue Nationale Contre le Cancer, the Nord/Pas-de-Calais region, and INTAS 05-1000008-8223.

1. Lang F, Foller M, Lang KS, Lang PA, Ritter M, Gulbins E *et al.* Ion channels in cell proliferation and apoptotic cell death. *J Membr Biol* 2005; **205**: 147–157.
2. Razik MA, Cidlowski JA. Molecular interplay between ion channels and the regulation of apoptosis. *Biol Res* 2002; **35**: 203–207.

3. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines – part 1. *J Urol* 2005; **173**: 342–359.
4. Wang Z. Roles of K^+ channels in regulating tumour cell proliferation and apoptosis. *Pflugers Arch* 2004; **448**: 274–286.
5. Remillard CV, Yuan JX. Activation of K^+ channels: an essential pathway in programmed cell death. *Am J Physiol Lung Cell Mol Physiol* 2004; **286**: L49–L67.
6. Yu SP. Regulation and critical role of potassium homeostasis in apoptosis. *Prog Neurobiol* 2003; **70**: 363–386.
7. Hemmerlein B, Weseloh RM, Mello de Queiroz F, Knotgen H, Sanchez A, Rubio ME *et al.* Overexpression of Eag1 potassium channels in clinical tumours. *Mol Cancer* 2006; **5**: 41.
8. Pardo LA, Contreras-Jurado C, Zientkowska M, Alves F, Stuhmer W. Role of voltage-gated potassium channels in cancer. *J Membr Biol* 2005; **205**: 115–124.
9. Pardo LA, del Camino D, Sanchez A, Alves F, Bruggemann A, Beckh S *et al.* Oncogenic potential of EAG K(+) channels. *EMBO J* 1999; **18**: 5540–5547.
10. Rybalchenko V, Prevarskaya N, Van Coppenolle F, Legrand G, Lemonnier L, Le Bourhis X *et al.* Verapamil inhibits proliferation of LNCaP human prostate cancer cells influencing K^+ channel gating. *Mol Pharmacol* 2001; **59**: 1376–1387.
11. Skryma R, Van Coppenolle F, Dufy-Barbe L, Dufy B, Prevarskaya N. Characterization of Ca(2+)-inhibited potassium channels in the LNCaP human prostate cancer cell line. *Receptors Channels* 1999; **6**: 241–253.
12. Skryma RN, Prevarskaya NB, Dufy-Barbe L, Odessa MF, Audin J, Dufy B. Potassium conductance in the androgen-sensitive prostate cancer cell line LNCaP: involvement in cell proliferation. *Prostate* 1997; **33**: 112–122.
13. Laniado ME, Fraser SP, Djamgoz MB. Voltage-gated K(+) channel activity in human prostate cancer cell lines of markedly different metastatic potential: distinguishing characteristics of PC-3 and LNCaP cells. *Prostate* 2001; **46**: 262–274.
14. Abdul M, Hoosein N. Expression and activity of potassium ion channels in human prostate cancer. *Cancer Lett* 2002; **186**: 99–105.
15. Fraser SP, Grimes JA, Diss JK, Stewart D, Dolly JO, Djamgoz MB. Predominant expression of Kv1.3 voltage-gated K+ channel subunit in rat prostate cancer cell lines: electrophysiological, pharmacological and molecular characterisation. *Pflugers Arch* 2003; **446**: 559–571.
16. Ouadid-Ahidouch H, Van Coppenolle F, Le Bourhis X, Belhaj A, Prevarskaya N. Potassium channels in rat prostate epithelial cells. *FEBS Lett* 1999; **459**: 15–21.
17. Anderson JD, Hansen TP, Lenkowski PW, Walls AM, Choudhury IM, Schenck HA *et al.* Voltage-gated sodium channel blockers as cytostatic inhibitors of the androgen-independent prostate cancer cell line PC-3. *Mol Cancer Ther* 2003; **2**: 1149–1154.
18. Wible BA, Wang L, Kuryshev YA, Basu A, Haldar S, Brown AM. Increased K+ efflux and apoptosis induced by the potassium channel modulatory protein KChAP/PIAS3beta in prostate cancer cells. *J Biol Chem* 2002; **277**: 17852–17862.
19. Gessner G, Schonherr K, Soom M, Hansel A, Asim M, Baniahmad A *et al.* BKCa channels activating at resting potential without calcium in LNCaP prostate cancer cells. *J Membr Biol* 2005; **208**: 229–240.
20. Abdul M, Hoosein N. Voltage-gated sodium ion channels in prostate cancer: expression and activity. *Anticancer Res* 2002; **22**: 1727–1730.
21. Bennett ES, Smith BA, Harper JM. Voltage-gated Na^+ channels confer invasive properties on human prostate cancer cells. *Pflugers Arch* 2004; **447**: 908–914.
22. Diss JK, Archer SN, Hirano J, Fraser SP, Djamgoz MB. Expression profiles of voltage-gated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines. *Prostate* 2001; **48**: 165–178.
23. Diss JK, Stewart D, Pani F, Foster CS, Walker MM, Patel A *et al.* A potential novel marker for human prostate cancer: voltage-gated sodium channel expression *in vivo*. *Prostate Cancer Prostatic Dis* 2005; **8**: 266–273.
24. Fraser SP, Salvador V, Manning EA, Mizal J, Altun S, Raza M *et al.* Contribution of functional voltage-gated Na+ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: I. Lateral motility. *J Cell Physiol* 2003; **195**: 479–487.
25. Mycielska ME, Fraser SP, Szatkowski M, Djamgoz MB. Contribution of functional voltage-gated Na+ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: II. Secretory membrane activity. *J Cell Physiol* 2003; **195**: 461–469.
26. Scorey N, Fraser SP, Patel P, Pridgeon C, Dallman MJ, Djamgoz MB. Notch signalling and voltage-gated Na^+ channel activity in human prostate cancer cells: independent modulation of *in vitro* motility. *Prostate Cancer Prostatic Dis* 2006; **9**: 399–406.
27. Rosenthal E, Shapiro E, Lepor H. Characterization of 1,4, dihydropyridine calcium channel binding sites in the human prostate. *J Urol* 1990; **144**: 1539–1542.
28. Connor J, Sawczuk IS, Benson MC, Tomashefsky P, O'Toole KM, Olsson CA *et al.* Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. *Prostate* 1988; **13**: 119–130.
29. Martikainen P, Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. *Prostate* 1990; **17**: 175–187.
30. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. *Endocr Relat Cancer* 1999; **6**: 503–519.
31. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update. *Prostate Suppl* 1998; **8**: 74–79.
32. Kim JH, Shin SY, Yun SS, Kim TJ, Oh SJ, Kim KM *et al.* Voltage-dependent ion channel currents in putative neuroendocrine cells dissociated from the ventral prostate of rat. *Pflugers Arch* 2003; **446**: 88–99.
33. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. *Ann Oncol* 2001; **12** (Suppl 2): S141–S144.
34. Fixemer T, Remberger K, Bonkhoff H. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. *Prostate* 2002; **53**: 118–123.
35. Xue Y, Verhofstad A, Lange W, Smedts F, Debruyne F, de la Rosette J *et al.* Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: cell kinetic features of neuroendocrine cells in the human prostate. *Am J Pathol* 1997; **151**: 1759–1765.
36. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. *Prostate* 2001; **48**: 7–15.
37. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. *Prostate* 2002; **50**: 179–188.
38. Mariot P, Vanoverberghe K, Lalevee N, Rossier MF, Prevarskaya N. Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. *J Biol Chem* 2002; **277**: 10824–10833.
39. Thebault S, Roudbaraki M, Sydorenko V, Shuba Y, Lemonnier L, Slomianny C *et al.* alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells. *J Clin Invest* 2003; **111**: 1691–1701.
40. Vanoverberghe K, Mariot P, Vanden Abeele F, Delcourt P, Parys JB, Prevarskaya N. Mechanisms of ATP-induced calcium signaling and growth arrest in human prostate cancer cells. *Cell Calcium* 2003; **34**: 75–85.
41. Hajnoczky G, Davies E, Madesh M. Calcium signaling and apoptosis. *Biochem Biophys Res Commun* 2003; **304**: 445–454.
42. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. *Nat Rev Mol Cell Biol* 2003; **4**: 552–565.
43. Rizzuto R, Pinton P, Ferrari D, Chami M, Szabadkai G, Magalhaes PJ *et al.* Calcium and apoptosis: facts and hypotheses. *Oncogene* 2003; **22**: 8619–8627.
44. Lipskaia L, Lompre AM. Alteration in temporal kinetics of Ca2+ signaling and control of growth and proliferation. *Biol Cell* 2004; **96**: 55–68.
45. Munaron L, Antoniotti S, Lovisolo D. Intracellular calcium signals and control of cell proliferation: how many mechanisms? *J Cell Mol Med* 2004; **8**: 161–168.
46. Santella L, Ercolano E, Nusco GA. The cell cycle: a new entry in the field of Ca^{2+} signaling. *Cell Mol Life Sci* 2005; **62**: 2405–2413.
47. Parekh AB, Putney Jr JW. Store-operated calcium channels. *Physiol Rev* 2005; **85**: 757–810.
48. Hoth M, Penner R. Depletion of intracellular calcium stores activates a calcium current in mast cells. *Nature* 1992; **355**: 353–356.
49. Vanden Abeele F, Skryma R, Shuba Y, Van Coppenolle F, Slomianny C, Roudbaraki M *et al.* Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells. *Cancer Cell* 2002; **1**: 169–179.
50. Zhang SL, Yu Y, Roos J, Kozak JA, Deerinck TJ, Ellisman MH *et al.* STIM1 is a Ca^{2+} sensor that activates CRAC channels and migrates from the Ca^{2+} store to the plasma membrane. *Nature* 2005; **437**: 902–905.
51. Liou J, Kim ML, Heo WD, Jones JT, Myers JW, Ferrell Jr JE *et al.* STIM is a Ca^{2+} sensor essential for Ca^{2+}-store-depletion-triggered Ca^{2+} influx. *Curr Biol* 2005; **15**: 1235–1241.
52. Feske S, Gwack Y, Prakriya M, Srikanth S, Puppel SH, Tanasa B *et al.* A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. *Nature* 2006; **441**: 179–185.
53. Pedersen SF, Owsianik G, Nilius B. TRP channels: an overview. *Cell Calcium* 2005; **38**: 233–252.
54. Ramsey IS, Delling M, Clapham DE. An introduction to TRP channels. *Annu Rev Physiol* 2006; **68**: 619–647.
55. Vanden Abeele F, Lemonnier L, Thebault S, Lepage G, Parys JB, Shuba Y *et al.* Two types of store-operated Ca^{2+} channels with different activation modes and molecular origin in LNCaP human prostate cancer epithelial cells. *J Biol Chem* 2004; **279**: 30326–30337.
56. Vanden Abeele FV, Shuba Y, Roudbaraki M, Lemonnier L, Vanoverberghe K, Mariot P *et al.* Store-operated Ca(2+) channels in prostate cancer epithelial cells: function, regulation, and role in carcinogenesis. *Cell Calcium* 2003; **33**: 357–373.
57. Vanden Abeele F, Roudbaraki M, Shuba Y, Skryma R, Prevarskaya N. Store-operated Ca^{2+} current in prostate cancer epithelial cells. Role of endogenous Ca^{2+} transporter type 1. *J Biol Chem* 2003; **278**: 15381–15389.
58. Kahr H, Schindl R, Fritsch R, Heinze B, Hofbauer M, Hack ME *et al.* CaT1 knock-down strategies fail to affect CRAC channels in mucosal-type mast cells. *J Physiol* 2004; **557**: 121–132.
59. Peng JB, Chen XZ, Berger UV, Vassilev PM, Tsukaguchi H, Brown EM *et al.* Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption. *J Biol Chem* 1999; **274**: 22739–22746.
60. Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H. Expression of the Ca^{2+}-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. *Oncogene* 2003; **22**: 7858–7861.
61. Peng JB, Zhuang L, Berger UV, Adam RM, Williams BJ, Brown EM *et al.* CaT1 expression correlates with tumor grade in prostate cancer. *Biochem Biophys Res Commun* 2001; **282**: 729–734.
62. Wissenbach U, Niemeyer BA, Fixemer T, Schneidewind A, Trost C, Cavalie A *et al.* Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer. *J Biol Chem* 2001; **276**: 19461–19468.

63. Schwarz EC, Wissenbach U, Niemeyer BA, Strauss B, Philipp SE, Flockerzi V *et al.* TRPV6 potentiates calcium-dependent cell proliferation. *Cell Calcium* 2006; **39**: 163–173.
64. Bodding M, Fecher-Trost C, Flockerzi V. Store-operated Ca^{2+} current and TRPV6 channels in lymph node prostate cancer cells. *J Biol Chem* 2003; **278**: 50872–50879.
65. Thomas AP, Bird GS, Hajnoczky G, Robb-Gaspers LD, Putney Jr JW. Spatial and temporal aspects of cellular calcium signaling. *FASEB J* 1996; **10**: 1505–1517.
66. Thebault S, Flourakis M, Vanoverberghe K, Vandermoere F, Roudbaraki M, Lehen'kyi V *et al.* Differential role of transient receptor potential channels in Ca^{2+} entry and proliferation of prostate cancer epithelial cells. *Cancer Res* 2006; **66**: 2038–2047.
67. Kyprianou N, Chon J, Benning CM. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. *Prostate Suppl* 2000; **9**: 42–46.
68. Benning CM, Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. *Cancer Res* 2002; **62**: 597–602.
69. Pigozzi D, Ducret T, Tajeddine N, Gala JL, Tombal B, Gailly P. Calcium store contents control the expression of TRPC1, TRPC3 and TRPV6 proteins in LNCaP prostate cancer cell line. *Cell Calcium* 2006; **39**: 401–415.
70. Vanoverberghe K, Vanden Abeele F, Mariot P, Lepage G, Roudbaraki M, Bonnal JL *et al.* Ca^{2+} homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. *Cell Death Differ* 2004; **11**: 321–330.
71. Prevarskaya N, Skryma R, Shuba Y. Ca^{2+} homeostasis in apoptotic resistance of prostate cancer cells. *Biochem Biophys Res Commun* 2004; **322**: 1326–1335.
72. McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. *Nature* 2002; **416**: 52–58.
73. Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM *et al.* A TRP channel that senses cold stimuli and menthol. *Cell* 2002; **108**: 705–715.
74. Tsavaler L, Shapero MH, Morkowski S, Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. *Cancer Res* 2001; **61**: 3760–3769.
75. Thebault S, Lemonnier L, Bidaux G, Flourakis M, Bavencoffe A, Gordienko D *et al.* Novel role of cold/menthol-sensitive transient receptor potential melastatine family member 8 (TRPM8) in the activation of store-operated channels in LNCaP human prostate cancer epithelial cells. *J Biol Chem* 2005; **280**: 39423–39435.
76. Zhang L, Barritt GJ. Evidence that TRPM8 is an androgen-dependent Ca^{2+} channel required for the survival of prostate cancer cells. *Cancer Res* 2004; **64**: 8365–8373.
77. Bidaux G, Roudbaraki M, Merle C, Crepin A, Delcourt P, Slomianny C *et al.* Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement. *Endocr Relat Cancer* 2005; **12**: 367–382.
78. Bonkhoff H, Fixemer T, Remberger K. Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. *Prostate* 1998; **34**: 251–258.
79. Bruckheimer EM, Spurgers K, Weigel NL, Logothetis C, McDonnell TJ. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. *J Urol* 2003; **169**: 1553–1557.
80. Nantermet PV, Xu J, Yu Y, Hodor P, Holder D, Adamski S *et al.* Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland. *J Biol Chem* 2004; **279**: 1310–1322.
81. Fuessel S, Sickert D, Meye A, Klenk U, Schmidt U, Schmitz M *et al.* Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. *Int J Oncol* 2003; **23**: 221–228.
82. Kiessling A, Fussel S, Schmitz M, Stevanovic S, Meye A, Weigle B *et al.* Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. *Prostate* 2003; **56**: 270–279.
83. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE *et al.* Implication of cell kinetic changes during the progression of human prostatic cancer. *Clin Cancer Res* 1995; **1**: 473–480.
84. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK *et al.* Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. *Cancer Res* 2003; **63**: 4196–4203.
85. Furst J, Gschwentner M, Ritter M, Botta G, Jakab M, Mayer M *et al.* Molecular and functional aspects of anionic channels activated during regulatory volume decrease in mammalian cells. *Pflugers Arch* 2002; **444**: 1–25.
86. Okada Y, Shimizu T, Maeno E, Tanabe S, Wang X, Takahashi N. Volume-sensitive chloride channels involved in apoptotic volume decrease and cell death. *J Membr Biol* 2006; **209**: 21–29.
87. Shen MR, Yang TP, Tang MJ. A novel function of BCL-2 overexpression in regulatory volume decrease. Enhancing swelling-activated Ca(2+) entry and Cl(−) channel activity. *J Biol Chem* 2002; **277**: 15592–15599.
88. Lemonnier L, Shuba Y, Crepin A, Roudbaraki M, Slomianny C, Mauroy B *et al.* Bcl-2-dependent modulation of swelling-activated Cl- current and ClC-3 expression in human prostate cancer epithelial cells. *Cancer Res* 2004; **64**: 4841–4848.
89. Shuba YM, Prevarskaya N, Lemonnier L, Van Coppenolle F, Kostyuk PG, Mauroy B *et al.* Volume-regulated chloride conductance in the LNCaP human prostate cancer cell line. *Am J Physiol Cell Physiol* 2000; **279**: C1144–C1154.
90. Lemonnier L, Prevarskaya N, Shuba Y, Vanden Abeele F, Nilius B, Mazurier J *et al.* Ca^{2+} modulation of volume-regulated anion channels: evidence for colocalization with store-operated channels. *FASEB J* 2002; **16**: 222–224.
91. Lemonnier L, Lazarenko R, Shuba Y, Thebault S, Roudbaraki M, Lepage G *et al.* Alterations in the regulatory volume decrease (RVD) and swelling-activated Cl^- current associated with neuroendocrine differentiation of prostate cancer epithelial cells. *Endocr Relat Cancer* 2005; **12**: 335–349.
92. Duan D, Winter C, Cowley S, Hume JR, Horowitz B. Molecular identification of a volume-regulated chloride channel. *Nature* 1997; **390**: 417–421.